Malignant disease in adolescence is relatively rare, yet accounts for a sizeable morbidity and mortality, particularly in the developed world. Professionals active in the field recognise that teenagers and young adults with cancer are a particularly challenging group with which to work, bringing as they do extremes of happiness, conflict, fun and poignancy. Only in recent years have the needs of this group started to be addressed in a systematic manner. Patterns of cancer occurrence in this group differ from both children and older adults and adolescents with cancer have very specific psychological, educational and social support needs. The Expert Advisory Group in Cancer to the Chief Medical Officers of England & Wales 1 has recognised these needs and recommends the formation of specialist units for adolescents with cancer. The World Health Organization defines adolescents as those individuals between 10-20 years of age. Whilst this approach has the advantage of simplicity, the WHO definition does not succeed in framing the more functionally held view of adolescence as a transition from childhood to adulthood.
Defining adolescence
There are many alternative ways to try and define adolescence varying from very simple constructs, such as physical growth and pubertal development, through to social constructs, such as adolescence as a period of chronic crisis where extreme variations in behaviour are the norm. Adolescence can most helpfully be viewed as a period of life where tasks such as establishing personal identity, establishing independence, making occupational choices and making philosophical choices are initiated 3 , although these tasks continue throughout life. Practically, adolescence needs to be formally recognised as being a flexible concept that encompasses most individuals within the age range 14-22 years, but stretching several years in either direction. In contrast to the broadly accepted view of adolescence as a 'time apart' somewhere between childhood and adulthood, it should be viewed as containing elements of both of these. Adolescents are both adults and children.
The impact of cancer on the adolescent
Cancer challenges the adolescent's sense of self-esteem, leading to feelings of loss of control at a time of life when self-image is pivotal to normal development. Periods of hospitalisation and illness may contribute to increased dependence on parents, who quite naturally feel protective and want to take over care. Peer contact will decrease at a rime when peer group acceptance is crucial. Reliance on family for financial support and on health care professionals for treatment contributes to a feeling of lack of independence. Treatment effects of hair loss or weight loss from chemotherapy, weight gain from steroids, scarring from surgery, skin effects and growth disorders from radiotherapy, will influence the individual's identity and self-esteem 3 . This, combined with treatment effects on fertility, may affect a young person's developing sexual identity.
Illness and treatment changes the lifestyle of teenagers. Education can be disrupted, future occupational plans may be changed, either out of necessity because of disease progression or because of the perceived threat of cancer to life. Questions arise about competence or appropriateness of obtaining employment, insurance, a mortgage and even a partner. These factors may be more important to adolescents than the prospect of dying.
It is essential that professionals involved in caring for adolescents have a clear appreciation of these developmental tasks in order to try and help these young people restore some degree of normality for themselves. This is not a process that is always easily facilitated within formal institutions like hospitals.
Teenagers and young adults need space, both physical and psychological, to vent anger or frustration in the face of challenges to their independence. Their right to independence must be cherished and restored, most notably by respecting their rights to information and encouraging their full participation in decision making. Knowledge of cancer has been positively related to self-image and it has been suggested that increased knowledge may help with adjustment 4 . Despite this, adolescents often need and want the support of their parents, siblings or partners in decision making. Family members should be encouraged to provide this but without attempting to wrest control from the patient.
Peer group involvement is pivotal for teenagers, services for adolescents with cancer should be organised to provide peer contact and to encourage return to school, college or work at the earliest opportunity. Physical facilities that allow for normal adolescent pursuits such as study, music, sport, games or socialising are likely to be helpful to a sense of self-worth.
Epidemiology of adolescent cancer
There is a relative dearth of clear epidemiological data about cancer in adolescence. Most registry data classifies incidence within 5 year age bands which implies that to be comprehensive about adolescent cancer it is necessary to look at the age range 10-24 years. Additional difficulties are contributed by the registration of most cancers according to site of origin. This approach is reasonable for adult type carcinomas but does not reflect the diversity of histological diagnosis seen in teenagers and young adults. A recent study from New South Wales 5 recommends using the childhood classification scheme 6 modified for adolescent age groups. Cancer incidence in 10-19 year olds based on data from the US, Canada, England and Wales 7 and New South Wales 6 is shown in Table 1 . The Yorkshire Tumour Registry indicates that the incidence of cancers for males and females appears to increase through the 10-14, 15-19 and 20-24 age ranges 8 ( Table 2 ). The sex ratio also appears to change with increasing age. Most registries appear to show a small male predominance up to age 14 years, but the Yorkshire data demonstrate a marked shift to female predominance in the 20-24 year range even though carcinoma cervix in situ is excluded. This is largely related to a female There is a clear change in the types of cancer that occur during adolescence. This is summarised in Table 3 . In early adolescence, the leukaemias and central nervous system tumours predominate, however, during mid and late adolescence lymphomas become the main single tumour group and the epithelial cancers become increasingly important. Bone sarcomas have a major contribution to early and mid adolescence but are relatively less common over the age of 20 years, whilst the incidence of germ cell tumours, particular of testis, increases. The classic embryonal tumours of childhood are rarely seen, even in the 10-14 year age range.
The change in pattern during mid and late adolescence can be clearly seen in the average number of cancer registrations in England and Wales between 1985-9 for different tumour groups (Table 4 ). These data are based on the ICD-9 classification scheme, so are subject to some of the problems of being site determined as discussed earlier.
Data from the Yorkshire Cancer Registry 9 for adolescents age 15-23 years between the years 1975-91 show a very similar pattern (Table 5 ). It should be of particular note that the number of diagnoses of carcinoma of cervix in situ is more or less equivalent to all other cancer registrations.
It is unclear what impact the number of young women with cervix in situ will have on the future incidence of invasive cervical carcinoma. Even within individual tumour groups, histological subtypes vary at different ages. Acute lymphoblastic leukaemia decreases in importance with increasing age when compared to the non-lymphoid leukaemias and T-cell disease is predominantly a disease of teenage males. Within the soft tissue sarcomas, rhabdomyosarcoma is the major subtype during childhood and early adolescence, but other subtypes, such as synovial sarcoma, malignant fibrosis histiocytoma and soft-part alveolar sarcoma, increase in importance with increasing age. There are very poor data on true incidence patterns of these subtypes. 
Specific tumours of adolescence
Many of the cancers that occur commonly in adolescence, such as the lymphomas, leukaemias, sarcomas and germ cell tumours, are discussed elsewhere in this publication. There is little reason at present for thinking that the management of colorectal, ovarian or breast carcinoma should differ from best recommended practice for slightly older adults, although it has been suggested 10 that sub-types of breast cancer in the very young adult group have a poor prognosis and could benefit from a coordinated, collaborative approach to management including the institution of multi-centre clinical trials. This approach could also apply to other common cancers.
The epithelial tumours of adolescence that are likely to be seen by paediatric oncologists as well as adult oncologists are nasopharyngeal and thyroid carcinoma.
Nasopharyngeal carcinoma
Nasopharyngeal carcinoma has been shown to have a bimodal distribution in the US, with the initial peak in adolescents. The incidence is about 1 in 100,000 in Europe and North America but is much more common in North Africa and South East Asia rising to 25 in 100,000 in Hong Kong 11 . Most cases in childhood and adolescence are of the undifferentiated histological sub-type with lesser numbers having non-keratinizing carcinoma. Both of these sub-types are associated with raised titres to Epstein-Barr virus and it has been suggested that antibodies to viral capsid antigen are a useful indicator of disease activity 12 . Squamous cell carcinoma rarely occurs in adolescence. Nasopharyngeal carcinoma may present with symptoms of local infiltration such as epistaxis, serous otitis media, hearing loss, trismus or cranial nerve palsies, but frequently will present with cervical lymphadenopathy as the only symptom. It needs to be distinguished from other nasopharyngeal malignancies such as rhabdomyosarcoma, PNET and non-Hodgkin's lymphoma or from lymphoma and thyroid carcinoma which may present with cervical lymphadenopathy.
Radiotherapy is the mainstay of treatment with recommended doses of 45-60 Gy 13 to primary volume that should include nasopharynx, sinuses, base of skull, cervical and supra clavicular lymph nodes. This may, of course, have significant long-term growth and endocrine sequelae in children and young adults. Xerostomia and muscle fibrosis will also be problematic. Surgery has been largely employed for biopsy but modern techniques of head and neck surgery may force this to be rethought.
Prognosis relates to modified TNM staging 11 . Radiotherapy gives an overall survival of about 50% 14 , T1-T2 tumours having a survival of 75% compared with 37% in T3-T4.
The role of chemotherapy is less clear, but a poor prognosis in advanced disease with radiotherapy alone has led to the addition of chemotherapy. A recent review 9 confirms the inconclusive influence of chemotherapy but many of the schedules would be viewed as suboptimal by today's standards of dose intensity. Local practice had been to use a combination of vincristine, cyclophosphamide, doxorubicin and methotrexate 15 in advanced disease, but others have suggested combinations of cisplatin and 5-fluorouracil 16 . Randomised clinical trials would help clarify the situation.
Thyroid cancer
Thyroid cancer is one of the more common epithelial tumours in adolescents (Table 4) . A recent 30 year review of 154 thyroid cancers in England and Wales occurring under the age of 15 years showed 68% to be of papillary (mixed) sub-type, 11% to be follicular and 17% to be medullary 17 . There was a clear female preponderance in young adolescent of 1:3.6 and anaplastic histology was rare. These figures are broadly in line with other studies. In recent years, there has been an apparent increase in the incidence of medullary thyroid carcinoma in young adults probably as a result of screening families with multiple endocrine neoplasia familial cancer syndromes (MEN Type 2a and 2b). At risk individuals are screened by measurement of calcitonin levels and early identification leads to improved survival rates following thyroidectomy 18 . Thyroid carcinoma most commonly presents with painless anterior cervical lymphadenopathy, although isolated thyroid nodules also occur. Pulmonary metastases are found in about 20% of patients with papillary thyroid cancer. Bone metastases are more likely to occur with follicular histology. Patients are usually euthyroid. Diagnostic and staging investigations should include thyroid scintiscan and CT scans of neck and chest, a raised serum calcitonin may indicate medullary cancer. The diagnosis of thyroid carcinoma depends on biopsy, either fine needle aspiration of thyroid nodule or excision biopsy of a lymph node.
Radical thyroidectomy with preservation of parathyroid glands and recurrent laryngeal nerve is the treatment of choice and will need to be combined with excision of all suspect lymph nodes, including cervical and mediastinal chains where necessary. In children and young adults, surgery is followed by a thyro-ablative dose of 131 I. This should be followed, after several months, by a further radioiodine scan to identify disease that may not be otherwise visible on routine radiology 19 . The presence of tumour outside of the thyroid is the indication for therapeutic doses of 131 I and this may need to be repeated on one or more occasions. Radioiodine therapy may be complicated by transient bone marrow suppression, sialadenitis, azoospermia and infertility. A recent study of women treated with 131 I reported two patients who gave birth to children with fatal birth defects and recommended avoiding pregnancy for up to 1 year after 131 I treatment 20 . Following treatment, patients should receive fully TSH suppressive doses of L-thyroxine. Serum thyroglobulin estimation may provide a useful marker of disease activity but follow-up should include careful clinical and radiological evaluation.
The long-term prognosis for young adults with differentiated thyroid carcinoma is good, with 15 year survival approaching 90% 21 , although the natural history is such that disease may recur after many years. Recurrence may need further surgery, radioiodine therapy or both. Other modalities such as external beam irradiation or chemotherapy have not been particularly successful. Doxorubicin is the only single agent to have recognised activity.
Current patterns of care for adolescents
It is axiomatic in paediatric oncology that multidisciplinary diagnosis, treatment and supportive care teams working in specialist tertiary centres have been a significant factor in the improved survival rates over the past Cancer in adoleicenco 25 years. In the UK, most children treated in United Kingdom Children's Cancer Study Group (UKCCSG) centres are entered into national or international trials or studies for their primary tumour treatment. Although figures are not easy to find, what data there is would suggest that the situation for adolescents is somewhat different. Analysis of UKCCSG registration for 1992^ shows that only 58% of 13 and 14 year olds were registered in UKCCSG centres compared to 73% of 10-12 year olds and 84% of 0-9 year olds. The implication of these data must be that an important minority of patients may still not be receiving appropriate treatment or supportive care.
The situation for adolescents over 15 years of age is less clear. Only a small minority of older teenagers are treated at UKCCSG centres, less than 100 being registered in 1995, mainly teenagers with paediatric type solid tumours. There is no overall population based database for those aged 15-24 years indicating where treatment is carried out. A recent study of epithelial tumours in adolescence included data of patterns of care in Yorkshire 9 . Only a small proportion of patients in the 15-23 year age range were treated outside their district of origin suggesting that few were referred to specialist centres.
The need for adolescent cancer centres
The case for having specialist units for adolescents with cancer is built upon two major premises. Firstly, that the perceived benefits of centralisation of care should lead to improved treatment and survival. Secondly, the special physical, psychological, social and educational needs of adolescents could best be served by centralising expertise within a single multidisciplinary team for a geographical region.
The first of these is now part of the paediatric oncology litany. There is a clear perception that centralisation of care leads to better survival particularly for childhood cancers 22 but this is still somewhat controversial for adult cancers. More compelling are the data indicating improved outcome for a range of cancers when patients are treated in clinical trials 23 . This seems to be borne out for paediatric tumours and some of the rarer adult rumours such as malignant teratoma 24 . There is also evidence that children not treated in specialist centres may be overtreated 25 . A recent study from the American Children's Cancer Group showed survival for adolescents with acute lymphoblastic leukaemia in the 16-21 year age group to be equivalent to the 10-15 year age group when treated on an identical protocol within paediatric institutions 26 . This is in contrast to current dogma that older adolescents have a significantly worse prognosis.
The arguments in favour of centralisation and entry into clinical trials are compelling and the development of adolescent units would encourage central registration and specific clinical trials for all cancer diagnostic groups. The development of these units would allow additional focus on psychosocial sequelae and late effects of therapy. Areas such as selfesteem, interpersonal relationships and employment prospects could be addressed systematically. Medical sequelae such as infertility or longterm handicaps following brain or spinal tumours could be studied in this age group.
Setting up adolescent units would not be without difficulties or controversy. Such units would be expensive, of the same order as paediatric oncology units. Advisory bodies recommend their formation 1 -24 but in the current system it is purchasing authorities that need to be convinced.
Ideally, units should be sited where both paediatric and adult oncology is practised, but unfortunately there are only a minority of UK centres where this occurs. There is a danger that professional rivalries may interfere with the development of such units. In order to succeed there needs to be agreement between paediatric oncologists, medical oncologists, radiotherapists, clinical haematologists and surgical oncologists, but no one of these groups has the skills to manage all the various cancer diagnoses. Adolescents can only benefit from a close and developing relationship between these different disciplines within an environment designed for their needs, and from a multi-disciplinary support team with expertise in the problems that are faced by this technically and emotionally challenging group of young people.
